Catalysts for $REGN
73 tracked
Mar 21, 2023
approval
EVKEEZA (EVINACUMAB-DGNB) — FDA approval
evinacumab
→
Nov 8, 2022
approval
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Oct 17, 2022
approval
DUPIXENT (DUPILUMAB) — FDA approval
dupilumab
→
Sep 28, 2022
approval
DUPIXENT (DUPILUMAB) — FDA approval
dupilumab
→
Jun 7, 2022
approval
DUPIXENT (DUPILUMAB) — FDA approval
dupilumab
→
May 20, 2022
approval
DUPIXENT (DUPILUMAB) — FDA approval
dupilumab
→
Dec 22, 2021
approval
DUPIXENT (DUPILUMAB) — FDA approval
dupilumab
→
Dec 22, 2021
approval
DUPIXENT (DUPILUMAB) — FDA approval
dupilumab
→
Dec 22, 2021
approval
DUPIXENT (DUPILUMAB) — FDA approval
dupilumab
→
Oct 20, 2021
approval
DUPIXENT (DUPILUMAB) — FDA approval
dupilumab
→
Oct 1, 2021
approval
DUPIXENT (DUPILUMAB) — FDA approval
dupilumab
→
Jun 14, 2021
approval
DUPIXENT (DUPILUMAB) — FDA approval
dupilumab
→
Apr 1, 2021
approval
PRALUENT (ALIROCUMAB) — FDA approval
alirocumab
→
Apr 1, 2021
approval
PRALUENT (ALIROCUMAB) — FDA approval
alirocumab
→
Feb 22, 2021
approval
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Feb 11, 2021
approval
EVKEEZA (EVINACUMAB-DGNB) — FDA approval
evinacumab
→
Feb 9, 2021
approval
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Feb 9, 2021
approval
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Nov 10, 2020
approval
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Jun 25, 2020
approval
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Jun 18, 2020
approval
DUPIXENT (DUPILUMAB) — FDA approval
dupilumab
→
Jun 18, 2020
approval
DUPIXENT (DUPILUMAB) — FDA approval
dupilumab
→
May 26, 2020
approval
DUPIXENT (DUPILUMAB) — FDA approval
dupilumab
→
Mar 10, 2020
approval
PRALUENT (ALIROCUMAB) — FDA approval
alirocumab
→
Jun 26, 2019
approval
DUPIXENT (DUPILUMAB) — FDA approval
dupilumab
→
Apr 26, 2019
approval
PRALUENT (ALIROCUMAB) — FDA approval
alirocumab
→
Apr 26, 2019
approval
PRALUENT (ALIROCUMAB) — FDA approval
alirocumab
→
Mar 20, 2019
approval
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Mar 11, 2019
approval
DUPIXENT (DUPILUMAB) — FDA approval
dupilumab
→
Jan 18, 2019
approval
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→